Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Tao Fan, Qiaoyi Zhang & Shuvayu S Sen. (2013) Persistence with weekly and monthly bisphosphonates among postmenopausal women: analysis of a US pharmacy claims administrative database. ClinicoEconomics and Outcomes Research 5, pages 589-595.
Read now
Read now
Olavi Ylikorkala. (2008) A more active role for gynecologists in the prevention of postmenopausal osteoporosis. Gynecological Endocrinology 24:6, pages 293-294.
Read now
Read now
Andrew Grey & Ian R Reid. (2006) Differences between the bisphosphonates for the prevention and treatment of osteoporosis. Therapeutics and Clinical Risk Management 2:1, pages 77-86.
Read now
Read now
Marc C Hochberg & René Rizzoli. (2006) Long-term experience with alendronate in the treatment of osteoporosis. Expert Opinion on Pharmacotherapy 7:9, pages 1201-1210.
Read now
Read now
Faustino R. Pérez-López & Gonzalo R. Pérez Roncero. (2006) Assessing the content and quality of information on the treatment of postmenopausal osteoporosis on the World Wide Web. Gynecological Endocrinology 22:12, pages 669-675.
Read now
Read now
J.J. AMY. (2005) HORMONES AND MENOPAUSE: PRO. Acta Clinica Belgica 60:5, pages 261-268.
Read now
Read now
Articles from other publishers (32)
Muhammad Hassan, Arash Maleki, Qian Ying, Nam Nguyen, Muhammad Sohail Halim, Yasir J. Sepah, Diana V. Do & Quan Dong Nguyen. (2019) Alendronate induced chorioretinitis: The importance of meticulous assessments. American Journal of Ophthalmology Case Reports 14, pages 21-25.
Crossref
Crossref
Mohd Parvez Khan, Kainat Khan, Prem Swaroop Yadav, Abhishek Kumar Singh, Aditi Nag, Paritosh Prasahar, Monika Mittal, Shyamsundar Pal China, Mahesh Chandra Tewari, Geet Kumar Nagar, Deepshikha Tewari, Arun Kumar Trivedi, Sabyasachi Sanyal, Amitabha Bandyopadhyay & Naibedya Chattopadhyay. (2016) BMP signaling is required for adult skeletal homeostasis and mediates bone anabolic action of parathyroid hormone. Bone 92, pages 132-144.
Crossref
Crossref
Toshimi Tando, Yuiko Sato, Kana Miyamoto, Mayu Morita, Tami Kobayashi, Atsushi Funayama, Arihiko Kanaji, Wu Hao, Ryuichi Watanabe, Takatsugu Oike, Masaya Nakamura, Morio Matsumoto, Yoshiaki Toyama & Takeshi Miyamoto. (2016) Hif1α is required for osteoclast activation and bone loss in male osteoporosis. Biochemical and Biophysical Research Communications 470:2, pages 391-396.
Crossref
Crossref
T. Nakamura, M. Shiraki, M. Fukunaga, T. Tomomitsu, A. C. Santora, R. Tsai, G. Fujimoto, M. Nakagomi, H. Tsubouchi, E. Rosenberg & S. Uchida. (2013) Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis—a double-blind, randomized, dose-finding study. Osteoporosis International 25:1, pages 367-376.
Crossref
Crossref
Philippe Ha-Vinh, Christine Guimond, Hélène Bourdel, Jean-Louis Ricard & Bertille Roche-Apaire. (2012) Respect des indications remboursables de l'ostéodensitométrie et des traitements de l'ostéoporose en médecine de ville. Journal de gestion et d'économie médicales Vol. 30:4, pages 266-278.
Crossref
Crossref
Masaru Kadowaki, Shinji Imade, Suguru Kuwata & Yuji Uchio. (2012) Sequential multiple insufficiency fractures around knee over 6 months in a patient with primary osteoporosis. European Journal of Orthopaedic Surgery & Traumatology 22:S1, pages 181-184.
Crossref
Crossref
Peter Vestergaard. (2012) Raloxifene for the treatment of postmenopausal osteoporosis. International Journal of Clinical Rheumatology 7:3, pages 261-269.
Crossref
Crossref
Abdulrahim A. Rouzi, Sharifa A. Al-Sibiani, Nawal S. Al-Senani, Raja M. Radaddi & Mohammed-Salleh M. Ardawi. (2012) Independent predictors of all osteoporosis-related fractures among healthy Saudi postmenopausal women: The CEOR Study. Bone 50:3, pages 713-722.
Crossref
Crossref
Yuuki AKAGI, Tomoyuki SAKAUE, Eiji YONEYAMA & Takao AOYAMA. (2011) Influence of Mineral Water on Absorption of Oral Alendronate in Ratsラットにおけるアレンドロネート経口投与時のミネラルウォーターによる吸収率への影響. YAKUGAKU ZASSHI 131:5, pages 801-807.
Crossref
Crossref
Ann Cranney. 2010. Osteoporosis. Osteoporosis
469
486
.
Jun Iwamoto, Atsushi Miyata, Yoshihiro Sato, Tsuyoshi Takeda & Hideo Matsumoto. (2009) Factors Affecting Discontinuation of Alendronate Treatment in Postmenopausal Japanese Women With Osteoporosis. Journal of the Chinese Medical Association 72:12, pages 619-624.
Crossref
Crossref
S. J. Edwards, M. J. Clarke, S. Wordsworth & J. Borrill. (2009) Indirect comparisons of treatments based on systematic reviews of randomised controlled trials. International Journal of Clinical Practice 63:6, pages 841-854.
Crossref
Crossref
Reiner Bartl & Bertha FrischReiner Bartl & Bertha Frisch. 2009. Osteoporosis. Osteoporosis
99
105
.
Rujuta H. Patel & Kenneth W. Lyles. 2009. Osteoporosis in Older Persons. Osteoporosis in Older Persons
71
81
.
Kou Katayama & Takeo Matsuno. (2008) Effects of Bisphosphonates on Fracture Incidence and Bone Metabolism in Rheumatoid Arthritis Patients in General Practice Taking Long-Term Corticosteroid Therapy. Clinical Drug Investigation 28:3, pages 149-158.
Crossref
Crossref
A. De Castro. (2007) Máxima evidencia y de mejor calidad en metaanálisis de bifosfonatos para el tratamiento de la osteoporosis en mujeres posmenopáusicas. Revista Española de Enfermedades Metabólicas Óseas 16:4, pages 71-81.
Crossref
Crossref
S. Kumar, L. Dare, J.A. Vasko-Moser, I.E. James, S.M. Blake, D.J. Rickard, S.-M. Hwang, T. Tomaszek, D.S. Yamashita, R.W. Marquis, H. Oh, J.U. Jeong, D.F. Veber, M. Gowen, M.W. Lark & G. Stroup. (2007) A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone 40:1, pages 122-131.
Crossref
Crossref
P. Vestergaard, N. R. Jorgensen, L. Mosekilde & P. Schwarz. (2006) Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk – a meta-analysis. Osteoporosis International 18:1, pages 45-57.
Crossref
Crossref
Reiner Bartl, Bertha Frisch, Emmo von Tresckow & Christoph Bartl. 2007. Bisphosphonates in Medical Practice. Bisphosphonates in Medical Practice
235
258
.
Jun Iwamoto, Tsuyoshi Takeda & Yoshihiro Sato. (2006)
Menatetrenone (Vitamin K
2
) and Bone Quality in the Treatment of Postmenopausal Osteoporosis
. Nutrition Reviews 64:12, pages 509-517.
Crossref
Crossref
René Rizzoli. (2016) Long-Term Use of Bisphosphonates in Osteoporosis. Women's Health 2:2, pages 309-315.
Crossref
Crossref
René Rizzoli. (2006) Long-term Outcome of Weekly Bisphosphonates. Clinical Orthopaedics & Related Research 443, pages 61-65.
Crossref
Crossref
Uri A Liberman. (2006) Long-Term Safety of Bisphosphonate Therapy for Osteoporosis. Drugs & Aging 23:4, pages 289-298.
Crossref
Crossref
Jean-Pierre DevogelaerYves BoutsenDaniel H Manicourt. (2005) Bisphosphonate therapy for the treatment of postmenopausal osteoporosis. Aging Health 1:3, pages 459-474.
Crossref
Crossref
Steven Boonen, Roland F. Laan, Ian P. Barton & Nelson B. Watts. (2005) Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporosis International 16:10, pages 1291-1298.
Crossref
Crossref
Shinji Uchida, Tadaaki Taniguchi, Takafumi Shimizu, Taro Kakikawa, Kotoba Okuyama, Masahiko Okaniwa, Hironori Arizono, Koichi Nagata, Arthur C. Santora, Masataka Shiraki, Masao Fukunaga, Tatsushi Tomomitsu, Yasuo Ohashi & Toshitaka Nakamura. (2005) Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. Journal of Bone and Mineral Metabolism 23:5, pages 382-388.
Crossref
Crossref
Chin Lee, Elke Hunsche, Robert Balshaw, Sheldon X. Kong & Thomas J. Schnitzer. (2005) Need for common internal controls when assessing the relative efficacy of pharmacologic agents using a meta-analytic approach: Case study of cyclooxygenase 2-selective inhibitors for the treatment of osteoarthritis. Arthritis & Rheumatism 53:4, pages 510-518.
Crossref
Crossref
L. Carreño Pérez. (2005) Tratamiento de la pérdida de masa ósea en la mujer postmenopáusica. Revista Clínica Española 205:7, pages 341-351.
Crossref
Crossref
D.J. Hosking, P. Geusens & R. Rizzoli. (2005) Osteoporosis therapy: an example of putting evidence-based medicine into clinical practice. QJM: An International Journal of Medicine 98:6, pages 403-413.
Crossref
Crossref
M.J. Gómez de Tejada Romero & M. Sosa Henríquez. (2005) ¿Qué queremos decir exactamente con “fracturas no vertebrales”? (o ¿por qué no llamar a las cosas por su nombre?). Revista Española de Enfermedades Metabólicas Óseas 14:3, pages 39-40.
Crossref
Crossref
Solomon Epstein. (2005) The Roles of Bone Mineral Density, Bone Turnover, and Other Properties in Reducing Fracture Risk During Antiresorptive Therapy. Mayo Clinic Proceedings 80:3, pages 379-388.
Crossref
Crossref
Marc C. Hochberg, Paul D. Miller, Richard D. Wasnich, Philip D. Ross & Susan Greenspan. (2004) Letter to the Editor. Bone 35:5, pages 1222-1224.
Crossref
Crossref